MedTrace Logo

Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test

NCT01032902 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2808

Last updated 2012-04-30

No results posted yet for this study

Summary

This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 rapid test. The device is intended to qualitatively detect the presence of antibodies against HIV-1/2 in oral fluid, whole blood (capillary and venous), serum or plasma. This study will assess the DPP® HIV 1/2 Screen assay's ability to detect HIV-1.

Conditions

  • HIV Infections

Interventions

DEVICE

In Vitro Diagnostic Device

For the detection of antibodies to HIV in serum, plasma, blood and oral fluid

Sponsors & Collaborators

  • Chembio Diagnostic Systems, Inc.

    lead INDUSTRY

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01032902 on ClinicalTrials.gov